September 8, 2020 7:07 pm Published by admin Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas https://clinicaltrials.gov/ct2/show/NCT03715933?term=DR5+INBRX109&rank=1 Go to Arm Intervention/treatment Experimental: Dose Escalation INBRX-109 will be escalated (3+3 design) in subjects with locally advanced or metastatic solid tumors including sarcomas. Drug: INBRX-109 – multivalent DR5 agonist antibody The active ingredient of INBRX-109 is a [...]
September 5, 2020 12:52 am Published by admin Hello my CS brothers and sisters! I wanted to tell you a story about my journey which might help some of you. Here are some details: –diagnosed in Feb 2017, Grade 1 pelvic CS, spread widely on and around the acetabulum. Offered a hemipelvectomy but refused. –May 2017 started proton radiation at what is now [...]
September 3, 2020 6:30 pm Published by admin A CS Warrior on the Facebook Chondrosarcoma Support Group entered a new Phase 2 clinical trial yesterday specifically for unresectable and metastatic conventional CS that combines a histone deacetylase inhibitor Belinostat (FDA approved for a type of lymphoma) with an experimental DNA hypomethylating agent Guadecitabine (https://clinicaltrials.gov/ct2/show/study/NCT04340843). The study is currently recruiting at Columbia Medical Center [...]
September 2, 2020 1:17 am Published by admin In September, we honor the gold ribbon in recognition of Childhood Cancer Awareness Month! ✨ Did you know cancer is the second leading cause of death in children under the age of 15? In 2020, approximately 11,000 children ages 1-14 will be diagnosed with cancer. Medical and technological advances, however, now provide that about 85% [...]
September 2, 2020 1:04 am Published by admin Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma clinicaltrials.gov Brief Summary: This phase II trial studies how well belinostat and SGI-110 (guadecitabine) work in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread to other places in the body (metastatic). [...]
August 31, 2020 3:55 pm Published by admin To view the video on YouTube, click here
August 29, 2020 12:52 am Published by admin Schwartz Hunts for Predictive Biomarkers in Soft Tissue Sarcoma Gary K. Schwartz, MD, highlights research that is being done with regard to genomic signatures in sarcoma, challenges faced with immunotherapy, and where the field is headed. Gary K. Schwartz, MD Although several research efforts have been dedicated to evaluating the use of immunotherapy in patients [...]
August 16, 2020 3:34 am Published by admin Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency Abstract One of the crucial challenges in the clinical management of cancer is resistance to chemotherapeutics. Multidrug resistance (MDR) has been intensively studied, and one of the most prominent mechanisms underlying MDR is overexpression of adenosine triphosphate (ATP)-binding cassette (ABC) transporters. Despite research efforts to develop compounds [...]
August 16, 2020 3:24 am Published by admin Results of a Prospective Phase 2 Study of Pazopanib in Patients With Surgically Unresectable or Metastatic Chondrosarcoma Warren Chow, MD1; Paul Frankel, PhD2; Chris Ruel, PhD2; Dejka M. Araujo, MD3; Mohammed Milhem, MBBS4; Scott Okuno, MD5; Lee Hartner, MD6; Samir Undevia, MD7; and Arthur Staddon, MD6 BACKGROUND: This single-arm, multicenter, phase 2 study evaluated the [...]
August 12, 2020 6:36 pm Published by admin A new article Treating Chondrosarcoma with Urgency and Compassion has just been posted on the Chondrosarcoma Web Site (www.csfshayna.org). You can find the article on the Commentaries page (www.csfshayna.org/commentaries-chondrosarcoma-foundation/). The article examines problems and challenges in treating Chondrosarcoma. The intent of the paper is to give some direction to patients and families who have been [...]
